Ad, Corporate Development, Strategic And Decision Analytics

Pharmaceutical / Biotech

AD, CORPORATE DEVELOPMENT, STRATEGIC AND DECISION ANALYTICS

EXP 10
-15 yrs

DEG Masters

RELO

BONUS

Job Description.

We are a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the innovation, development and commercialization of life-transforming therapeutic products. We are the global leader in complement inhibition, and has developed and markets Soliris (eculizumab) as a treatment for patients with PNH and aHUS, two debilitating, ultra-rare and life-threatening disorders caused by chronic uncontrolled complement activation. Soliris is currently approved in more than 40 countries for the treatment of PNH, and in the United States for the treatment of aHUS.

We are evaluating other potential indications for Soliris and is pursuing development of other innovative biotechnology product candidates in early stages of development.

Position Summary

The Decision Analysis (DA) Associate will fulfill an important role on the Strategic and Decision Analytics team by providing financial and analytical insight that will ultimately inform strategic decisions made by our executive Committee. This individual will lead financial evaluations and analyses that will help us prioritize and execute on internal and external growth opportunities.

In this role, the Decision Analytics (DA) Associate will drive regular, cross-functional collaboration with Corporate Strategy, Business Development, Commercial Operations, and Research and Development. The end product of these efforts will be reports and presentations delivered to C-level executive management, including the CEO, CFO, and the Chief Strategy and Portfolio Officer.

An ideal candidate possesses outstanding project management skills, strong analytical abilities, and advanced knowledge of corporate finance. The Decision Analytics Associate will be accountable to executive management for insight and decision frameworks that will guide portfolio investments, and external licensing and acquisition activity.

In addition to regular collaboration with business leaders, we expect this individual to supervise and develop direct reports. As such, we are seeking a seasoned professional with 8-10 years of experience working in dynamic and challenging environments, strong interpersonal skills, and a high degree of accountability. Work experience in the life sciences industry is strongly preferred

Cross-Functional Decision Analytics

Collaborate with Corporate Strategy to perform scenario modeling and financial analysis

Work with Commercial New Products evaluation and market research teams to forecast and analyze revenue opportunities from internal pipeline and external therapies

Team up with Business Development to develop financial and analytical frameworks that determine the expected Net Present Value and economic terms for licensing, partnership, and acquisition opportunities

Partner with Technical Operations and R&D Strategy teams to drive productivity and profitability analyses – e.g., Return on Invested Capital, Economic Value Added, and expected Net Present Value – for pipeline prioritization and assessment

Present findings to executive management and defend analyses and assumptions

Meet regularly with Accounting, Tax, and Treasury finance colleagues to ensure alignment on funding requirements for pipeline investments, licensing and acquisition opportunities

Collaborate with Accounting, Business Planning, IT, Tax, and Treasury colleagues to support the development of long-range financial strategy

Develop and regularly update licensing, merger and acquisition funding strategies and long-range capital allocation planning

Control analyses and models that support reports to executive management on financial implications and recommendations related to licensing and acquisition opportunities, including project peak revenue opportunity, risk-adjusted NPVs, ROIC, and accretion / dilution impact

Work with investment banking advisors to regularly inform executive management on our company’s valuation and financial positioning within the biopharmaceutical…